Retirement Planning Co of New England Inc. Grows Stake in Humana Inc. (NYSE:HUM)

Retirement Planning Co of New England Inc. increased its stake in shares of Humana Inc. (NYSE:HUM) by 4.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 966 shares of the insurance provider’s stock after buying an additional 43 shares during the quarter. Retirement Planning Co of New England Inc.’s holdings in Humana were worth $245,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Pzena Investment Management LLC lifted its position in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after purchasing an additional 1,103,132 shares during the period. FMR LLC lifted its position in Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares during the period. Retirement Systems of Alabama lifted its position in Humana by 735.9% during the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after purchasing an additional 192,801 shares during the period. Worldquant Millennium Advisors LLC acquired a new position in Humana during the third quarter valued at $50,102,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Humana by 42.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 391,657 shares of the insurance provider’s stock valued at $124,053,000 after purchasing an additional 115,820 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.37% of the stock is owned by corporate insiders.

Humana Stock Up 2.1 %

HUM opened at $269.86 on Wednesday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a market cap of $32.57 billion, a PE ratio of 27.12, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average price of $271.45 and a 200 day moving average price of $278.29.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.31%. Humana’s dividend payout ratio is presently 35.58%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HUM. JPMorgan Chase & Co. decreased their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. StockNews.com downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday. Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Truist Financial upped their price objective on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.